Both DNA damage and mitochondrial dysfunction are involved in novel oxadiazolo[3,4-d]pyrimidine nucleoside...

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Cancer Research

Background:

• The development of novel anti-cancer agents is crucial for effective tumor treatment.
• Exploring new chemical scaffolds like oxadiazolo[3,4-d]pyrimidine nucleoside derivatives offers potential therapeutic avenues.

Purpose of the Study:

• To synthesize and evaluate novel oxadiazolo[3,4-d]pyrimidine nucleoside derivatives for anti-tumor activity.
• To elucidate the underlying mechanisms of action for the most potent compounds.

Main Methods:

• Synthesis of eight novel oxadiazolo[3,4-d]pyrimidine nucleoside derivatives.
• In vitro anti-proliferative assays using MTT on human cancer cell lines (Hela, ECA109, HepG2, A549).
• Assessment of nitric oxide (NO) release, intracellular free Ca2+ levels, mitochondrial membrane potential, and DNA damage.

Main Results:

• Compounds VI and VIII demonstrated significant inhibition of cancer cell proliferation with IC50 values between 30-70 µM.
• Both active compounds induced nitric oxide (NO) release and intracellular free Ca2+ overloading.
• Mitochondrial dysfunction, evidenced by decreased mitochondrial membrane potential, and DNA damage were observed in HepG2 cells, particularly with compound VIII.

Conclusions:

• Compounds VI and VIII are potent anti-tumor agents with potential for further development.
• The anti-cancer effects are mediated through mechanisms including NO release, calcium overload, mitochondrial dysfunction, and DNA damage.
• Oxadiazolo[3,4-d]pyrimidine nucleoside derivatives represent a promising class of compounds for cancer therapy.